Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 214

1.

Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.

Adomaityte J, Farooq M, Qayyum R.

Thromb Haemost. 2008 Feb;99(2):338-42.

PMID:
18278183
[PubMed - indexed for MEDLINE]
2.

[Raloxifene in postmenopausal women].

Trémollières F, Ribot C.

Gynecol Obstet Fertil. 2006 Feb;34(2):147-53. Epub 2006 Feb 17. Review. French.

PMID:
16483822
[PubMed - indexed for MEDLINE]
3.

Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.

Cranney A, Adachi JD.

Drug Saf. 2005;28(8):721-30. Review.

PMID:
16048357
[PubMed - indexed for MEDLINE]
4.

Safety assessment of raloxifene over eight years in a clinical trial setting.

Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL.

Curr Med Res Opin. 2005 Sep;21(9):1441-52.

PMID:
16197663
[PubMed - indexed for MEDLINE]
5.
6.

Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women.

de Villiers TJ.

Climacteric. 2009;12 Suppl 1:108-11. Review.

PMID:
19811253
[PubMed - indexed for MEDLINE]
7.

Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.

Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A, Cummings S; Multiple Outcomes of Raloxifene Evaluation Investigators.

Obstet Gynecol. 2004 Oct;104(4):837-44.

PMID:
15458908
[PubMed - indexed for MEDLINE]
8.

Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.

Duvernoy CS, Yeo AA, Wong M, Cox DA, Kim HM.

J Womens Health (Larchmt). 2010 Aug;19(8):1459-65. doi: 10.1089/jwh.2009.1687.

PMID:
20626269
[PubMed - indexed for MEDLINE]
9.

[Which is the better choice, estrogen or SERMs in postmenopausal women?].

Shintani M.

Clin Calcium. 2004 Oct;14(10):105-10. Review. Japanese.

PMID:
15577140
[PubMed - indexed for MEDLINE]
10.

Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease.

Mosca L, Grady D, Barrett-Connor E, Collins P, Wenger N, Abramson BL, Paganini-Hill A, Geiger MJ, Dowsett SA, Amewou-Atisso M, Kornitzer M.

Stroke. 2009 Jan;40(1):147-55. doi: 10.1161/STROKEAHA.108.518621. Epub 2008 Oct 23.

PMID:
18948611
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Raloxifene: a review of its use in the prevention of invasive breast cancer.

Moen MD, Keating GM.

Drugs. 2008;68(14):2059-83. Review.

PMID:
18778124
[PubMed - indexed for MEDLINE]
12.

Raloxifene and risk for stroke based on the framingham stroke risk score.

Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D.

Am J Med. 2009 Aug;122(8):754-61. doi: 10.1016/j.amjmed.2009.01.033. Epub 2009 Jun 18.

PMID:
19540454
[PubMed - indexed for MEDLINE]
13.

Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.

Ensrud K, Genazzani AR, Geiger MJ, McNabb M, Dowsett SA, Cox DA, Barrett-Connor E.

Am J Cardiol. 2006 Feb 15;97(4):520-7. Epub 2006 Jan 4.

PMID:
16461049
[PubMed - indexed for MEDLINE]
14.

Carotid artery intima-media thickness after raloxifene treatment.

Mack WJ, Dhungana B, Dowsett SA, Keech CA, Feng M, Li Y, Hodis HN.

J Womens Health (Larchmt). 2007 Apr;16(3):370-8.

PMID:
17439382
[PubMed - indexed for MEDLINE]
15.

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.

Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK; Raloxifene Use for The Heart (RUTH) Trial Investigators.

N Engl J Med. 2006 Jul 13;355(2):125-37.

PMID:
16837676
[PubMed - indexed for MEDLINE]
Free Article
16.

The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women.

Neven P, Goldstein SR, Ciaccia AV, Zhou L, Silfen SL, Muram D.

Gynecol Oncol. 2002 May;85(2):388-90.

PMID:
11972407
[PubMed - indexed for MEDLINE]
17.

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.

Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N.

J Natl Cancer Inst. 2006 Jul 5;98(13):904-10.

PMID:
16818854
[PubMed - indexed for MEDLINE]
Free Article
18.

Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.

Layton D, Clarke A, Wilton LV, Shakir SA.

Osteoporos Int. 2005 May;16(5):490-500. Epub 2004 Aug 7.

PMID:
15309382
[PubMed - indexed for MEDLINE]
19.

Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism.

Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L.

Osteoporos Int. 2010 Sep;21(9):1591-7. doi: 10.1007/s00198-009-1091-y. Epub 2009 Oct 27.

PMID:
19859641
[PubMed - indexed for MEDLINE]
20.

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.

Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.

Curr Med Res Opin. 2008 Mar;24(3):807-13. doi: 10.1185/030079908X273282. Epub 2008 Feb 5.

PMID:
18254988
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk